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 Genetic Diagnostic Testing Method Patents: Tlteir Widespread Monopolization and tlze 
Need to Eliminate tlte Devastating Effects of Tlteir Abuse 
Frank Fiorello 
I. Introduction 
There are currently thousands of known genetic disorders, many quite serious and 
deadly. In fact, the World Health Organization estimates that there are over 10,000 
known "monogenic" human diseases alone, which only accounts for those diseases 
resulting from a mutation in a single gene out of tens of thousands of genes in human 
DNA. 1 In order to research and diagnose this ever-growing number of known genetic 
disorders, scientists and doctors have developed numerous methods of testing for the 
--J ~ ........ • -~· .... . ... ~. genetic-peculiarities .that cause them..-Countless people:hav.e. ah:eady .benefitecL.from,the.,,., . ............ , • .: .. ".· ....... ~ . 
knowledge gained through genetic testing, and this number will doubtlessly increase as 
more is constantly learned. 
The current, heated controversy surrounding genetic testing does not involve the 
testing itself, but rather the entitlement to and use of genetic testing method patents. A 
study conducted in 1995 determined that out of all genetics-related patents issued that 
year, diagnostic methods were the most popular? As the number of genetic testing 
method patents is rapidly growing, so is the need for clear guidelines as to whether such 
1 See Genes and Human Disease, WORLD HEALTH ORGANIZATION, 
http://www.who.int/genomics/public/geneticdiseases/en/index2.htrnl (last visited 
November 4, 2011). 
2 See Jon F. Merz, Disease Gene Patents: Overcoming Unethical Constraints on Clinical 
Laboratory Medicine, CLINICAL CHEMISTRY, March 1999, at 324, 324 (describing the 
Thomas et al. study on the number of "patents claiming gene sequences issued between 
1981 and 1994," diagnostics was the fifth most common, but in the follow-up 1995 study, 
it had become the most common). 
1 
patent claims are in fact valid and permissible. Based on several recent court decisions, 
some general guidelines have been established, but full clarity as to the validity of genetic 
testing method patents, and what makes certain claims valid and others invalid, has by no 
means yet been provided. 
Outside the courtroom, the patent-eligibility of genetic testing methods is causing 
quite a stir in the moral and political realm. The Constitution, as well as public policy, 
dictates that the availability of patents over inventions will promote "the progress of 
science and the useful arts."3 The question is, however, with respect to genetic testing 
method patents, "to what extent" and "at what expense"? Should doctors and scientists be 
able to rely on the fact that their new genetic testing method can be patented so that they 
will be encouraged to discover it in the first place? Or should certain limits and 
restrictions.be-"put-in-place.-s.othat-holders.ofs_uchpatents.are .. unable.to .. cease.-or ............ ,iJJ!.I ........ ~~ .. , .. :~v•"·-""J:.:l.'Ql.~'-'\.•'V...,..J!:; 
discourage further testing using their discovered method? 
This paper will delve further into the details of genetic diagnostic testing and its 
many flavors and varieties, as well as discuss the importance and need for such testing 
methods, in Part II below. Part III will take a further look into the current status of case 
law regarding genetic testing method patentability. As will be shown below in Part IV, 
there are several valid arguments both for and against the patentability of genetic 
diagnostic tests. Part V will demonstrate, however, that it is in the public's best interests 
3 See Rebecca S. Eisenberg, Patents and the Progress of Science: Exclusive Rights and 
Experimental Use, 56 U. CHI. L. REv. 1017, 1017 (1989) ("The patent laws confer 
exclusive rights in inventions and discoveries in furtherance of a constitutional purpose 
'To Promote the Progress of Science and useful Arts.' Yet the idea that exclusive rights 
in new knowledge will promote scientific progress is counterintuitive to many observers 
of research science, who believe that science advances most rapidly when the community 
enjoys free access to new discoveries."). 
2 
to :further restrict monopolization via broad genetic testing patents and allow all 
diagnostic and experimental uses of those methods to occur without risk of infringement. 
II. What is genetic diagnostic testing? 
"Genetic diagnostics analyze the sequence of a specific piece of DNA" and allow 
scientists and doctors to look for kno\Vll genetic disorders.4 Genetic testing involves "a 
laboratory procedure [for] detecting the presence or absence of, or change in, a particular 
gene or chromosome, including an indirect test for a gene product or other specific 
metabolite that is primarily indicative of a specific genetic change," so it is needless to 
say a highly complex, nuanced field of study. 5 Thorough knowledge and understanding 
e tJ.i-<\ •. ..._~:, .;··;..-.;.·.~~~ ,.,~,.,_,,_oEthedetaile.d p.ro.c.esses.~b~.hind:co.lh~cting .genetic .. data-is.needed,. especially~hy .. doctors, .. ~· ... ..,,,.,_ .. , ............. ~ .... ~·--·~····· .. · ~ 
as even interpreting the results of a genetic test is no easy feat. 6 By analyzing this data, 
doctors can inform patients of their susceptibility to developing certain genetic diseases 
and their chances of passing on those diseases to their offspring. 7 Knowledge of this 
information can not only "guide their life choices", such as the choice of whether to 
conceive a child knowing it will be at high risk of developing a disease or to seek out a 
4 See Asher Hodes, Diagnosing Patentable Subject Matter, 26 BERKELEY TECH. L.J. 225, 
243-244 (2011). 
5 See Sirpa Saini et. al., Patenting and licensing in genetic testing: ethical, legal and 
social issues, EUROPEAN JOURNAL OF HUMAN GENETICS, May 2008, at S10, S13. 
6 SeeS. Ayme et. al., Patenting and licensing in genetic testing: Recommendations of the 
European Society of Human Genetics, EUROPEAN JOURNAL OF HUMAN GENETICS, May 
2008, at S3, SS (describing how "the complexity in the interpretation of the results and in 
intellectual property (IP) protection will [most likely] increase."). 
7 See id. at S4-S5. 
3 
donor, but it can lead to the availability of treatment of a disease that would not otherwise 
beknown.8 
The fact that a given genetic test is only useful if it aims to detect "a known, 
described" genetic disorder, it is not uncommon for the discoverer of a new "disease 
gene" to not only patent the gene itself, but also obtain a patent over its associated genetic 
diagnostic testing methods.9 For example, Myriad, a case that will be discussed below, 
involved the genes BRCA1 and BRCA2, which they discovered were linked to breast and 
ovarian cancer. 10 Myriad patented not only the BRCA genes, but also several genetic 
diagnostic testing methods essentially comprising simply "analyzing" genes to seek out 
the BRCA mutation and ways of studying potential cancer treatments using the disease 
gene as a guideline. 11 The patented BRACAnalysis Test requires the test-taker to seek a 
.. healthcare .. pr.ovider.to.0btain.fh;>m-them a blood. sample that.must be.sent.to Myriad's ,._,, 
laboratories12 as Myriad is the only entity currently able to perform the full test. 13 Myriad 
charges approximately $3,200 for the BRACAnalysis test, which is the source of 80% of 
the company's revenue, and does not accept all insurance plans. 14 If one tests positive 
8 See Asher Hodes, supra note 4, at 248. 
9 See Saini, supra note 5, at S 13 (explaining that genetic testing methods accompanying 
newly discovered genetic mutations are also often patented together with the mutations 
mainly because "[o]nce a link between a disease and a precise genetic defect has been 
established, the relevant diagnostic test can be relatively easily developed."). 
10 See generally Ass'n for Molecular Pathology v. USPTO, No. 2010-1406,2011 U.S. 
App. LEXIS 15649 (Fed. Cir. July 29, 2011). 
11 See id at *9-10. 
12 See How Do I Get Tested?, BRACANALYSIS, http://www.bracnow.com/considering-
testing/get-tested.php (last visited December 6, 2011 ). 
13 See Janice M. Mueller, Facilitating Patient Access to Patent-Protected Genetic 
Testing, 111-112 (University of Pittsburgh Legal Studies Research Paper Series, Working 
Paper No. 2010-32, 2010), available at http://ssm.com/abstract=1694760. 
14 See id ("Myriad ... , a for-profit corporation, derives 80% of its revenues from its 
proprietary BRACAnalysis® testing, which it characterizes as 'the standard of care in 
identification of individuals with hereditary breast and ovarian cancer. H'). 
4 
under the BRACAnalysis Test, it signifies the existence of a genetic mutation in a BRCA 
gene that is associated with a high risk for developing breast or ovarian cancer15 and also 
means that close blood relatives also have a 50% chance of having the same mutation. 16 
In recommending possible remedial measures, Myriad goes so far as to suggest breast 
and ovary removal surgery or chemoprevention, 17 and this is all based on merely having a 
higher probability for developing the disease and without providing the patient any 
opportunity to obtain a second opinion.18 
Genetic testing does not only occur on the gene level, but also on the 
chromosomal and protein levels, as different tests examine mutations on any size level. 19 
Genetic tests are conducted for several different purposes, including, but not limited to: 
diagnostic testing when a person shows signs of a certain genetic disorder or wants to 
.. ~ .knowtheir chanc.es. for:developing.a.given disorder that runs in their family (e.g ...... . 
BRACAAnalysis); preconception testing to determine whether individuals are carriers of 
a genetic disorder and thus more likely to pass it onto their offspring; prenatal testing on 
pregnant women test women at high-risk for producing children with genetic disorders; 
newborn screening, currently the most widely used type; and pharmacogenetic testing, 
which examines the effects a given drug has on certain genes, which is used in the rapidly 
15 See Positive: What Does My Result Mean?, BRACANALYSIS, 
http://www.bracnow.com/understanding-my-results/positive-results.php (last visited 
December 6, 2011). 
16 See Positive: What Should I Do Now?, BRACANALYSIS, 
http://www.bracnow.com/understanding-my-results/positive-do-now.php (last visited 
December 6, 2011). 
17 See BRACANALYSIS, supra note 15. 
18 See Mueller, supra note 13, at Ill. 
19 See FAQ About genetic Testing, GENOME.GOV, http://www.genome.gov/19516567 (last 
visited December 6, 2011). 
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growing and promising field ofphannacogenetics?0 Though the majority of genetic tests 
are performed for medical purposes, as seen above, and thus require consultation with a 
healthcare provider, there are also a number of direct-to-consumer genetic tests that do 
not.21 Direct-to-consumer tests are most commonly used not only to make test-takers 
aware of certain general health implications, but also for non-medical purposes such as 
uncovering ancestry and providing insight as to one's personality-related genetic 
information. 22 
III. Are genetic diagnostic tests currently patent-eligible? 
In recent years alone, the Court has gone back and forth several times, seemingly 
· •. v "' •• establishing,_workableJegal tests.to .determine whetherua genetic.testing.method claim.is ......... , "" ........ ~ ........ , 
patentable or not, then proceeding to reject those principles in subsequent appeals. The 
single decision that had, perhaps, the greatest impact on the current state of genetic 
testing patentability did not concern a scientific-related method at all, but rather a method 
of hedging risk in commodities.23 Though several other important cases have thereafter 
been decided regarding the field of diagnostic testing method claims, it is yet to be 
determined whether almost any of them are final as each maintains certain grounds for 
further appeal. Until the Supreme Court expresses a final, catch-all decision regarding the 
patentability of genetic testing method claims in these cases, the field remains somewhat 
open and the guidelines blurry. 
20 See id 
21 See id 
22 See id 
23 See Bilski v. Kappas, 130 S. Ct. 3218, 3223 (2010) (explaining that Bilski obtained a 
patent on a method, or process, of hedging risk comprised purely of mental steps). 
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A. Before Bilski v. Kappas 
Dating as far back as 1793, it was established that in order for any invention to be 
patentable, it had to be the result of the inventor's "mental labor", and not simply the 
discovery of a law of nature. 24 This key principle remains in place today, forming the 
basis for § 101, the initial screening test applied to all claims to determine patentability 
based on whether or not, and the "abstract mental process" promoted in In re Bilski.25 
Between 1998 and the Court of Appeals' decision in 2008 in In re Bilski, the court made 
use of the UCT Test to determine method claim patentability, which looked only at 
whether the invention patented a "useful, concrete, and tangible result."26 The Court in In 
,;\-.···· ... r ·• re.Bilski, Jn,rejecting.thelUC.T Test.as. :;inadequate':, Jound.thatthe~only..,inquiry .. required,~,; .. -·· .. .', ~" ·-w~~ ... -1'··. 
is asking whether claim seeks to "claim a fundamental principle (such as an abstract idea) 
or a mental process", prescribing the infamous Machine-or-Transformation Test ("MoT 
Test") as the appropriate test.27 The MoT test, which was used as the exclusive 
24 See Timo Minssen & Robert M. Schwartz, US Patent Eligibility in the Wake of Bilski 
v. Kappas: 'Business as Usual' in an Age of New Technologies?, 29 BIOTECHNOLOGY L. 
REP. (forthcoming 2010) (manuscript at 12), available at 
http://ssm.com/abstract=1682574 ("Under section 3 of the 1793 registration system, 
patent holders claiming infringement were required to file a petition with the Secretary of 
State alleging under oath that their inventions were 'new and useful' and a product of the 
holder's 'mental labor or intellectual creation'."). 
25 See Eileen Kane, Patenting Genes and Genetic Methods: What's at Stake?, 6 J. Bus. & 
TECH. L. I, 20 ("(In re) Bilski ... concluded that the UCT test was 'inadequate' [and] 
framed its inquiry as 'whether Applicants are seeking to claim a fundamental principle 
(such as an abstract idea) or a mental process."'). 
26 See id (explaining that while the UCT Test was the governing standard during those 
ten years, "patent applicants relied on [it] to advance many inventions that lacked obvious 
tangibility, but which, arguably, could achieve a useful result."). 
27 See id ("The court announced that 'the machine-or-transformation (MOT) test outlined 
by the Supreme Court is the proper test to apply."'). 
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patentability test for about two years and led several decisions to be remanded and 
reversed (Prometheus v. Mayo), prescribed that "[a] claimed process is[] patent-eligible 
under § 101 if: (1) it is tied to a particular machine or apparatus, or (2) it transforms a 
particular article into a different state or thing."28 Due to the fact that the MoT Test was 
only used in In re Bilski on a business method claim, the ease with which this test was 
satisfied in the genetic testing method and other technological contexts would cause the 
test, as a whole, to be questioned for its generalized use among all method claims despite 
their nattire. 29 
B. The Bilski v. Kappos Decision 
... 9 ".11 H ... , ~- ......... ,, ... , e :• . .••• ,.The. Supreme .. Court:s :decision in Bilski. v ~ Kappos~("Bilski',') .re.YerberateS.•u.• .. , ., ..... -~· ......... . :., ... ;...,.,. .......... (>. ·.') .• ,._.,... 
throughout the opinions of seemingly all post-June 2010 method patent claim cases. 
Bilski took a clear, definitive test and turned it into a mere factor of a wider analysis. 
According to the U.S. Court of Appeals in In Re Bilski, the MoT Test was "the sole tesf' 
governing method, or process, claim patentability, and as long as the court could find that 
either prong was satisfied, the invention would be deemed patentable subject matter.30 
The Supreme Court, however, overturned this ruling on appeal, holding that, because the 
28 See In re Bilski, 545 F.3d 943, 956 (CA Fed. 2008) (holding that the Machine-or-
Transformation test was to be the sole governing patentability test for all method, or 
process, claims). 
29 See Kane, supra note 25, at 3 3 ("The legal standards from the business method patent 
cases arose to answer the central dilemma for that field - must an invention have a 
tangible form or be tied to physical processes? These were not the pressing questions 
from life science patenting. Instead, the central questions for biological patenting 
involved whether natural processes were being patented, and whether the preemption of 
basic scientific knowledge occurred."). 
30 See Bilski v. Kappos, 130 S. Ct. at 3223 (explaining the effect of the holding in the 
court below in In re Bilski). 
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machine-or-transformation test would too easily be satisfied in many instances and that it 
"violate[ d] [] statutory interpretation principles~~, the machine-or-transformation test is 
only "a useful and important clue, an investigative tool, for determining whether some 
claimed inventions are processes under § 10 1 ," and therefore not exclusive or required. 31 
Each of the three most controversial and important ongoing litigations involving the 
patentability of diagnostic testing methods began prior to the Supreme Court~ s words in 
Bilski and had their course drastically altered thereafter. 
C. Prometheus Labs v. Mayo 
The first of the three major cases decided after Bilski was Prometheus Labs., Inc. 
~"'"d •·l·'u.~~ •.•. ·.:··.,.··;\•-~·N-'.MayovCollaboratiye.Ser.v.s.-&.l\1ayo-.Clinic.Ro.chester . .(:.~:P.rometheus~')~:,.a.case.the, ....... ~•1··~.-.···-·· -·~·"'*''"'·"" .. , ............... .. 
Supreme Court remanded the day after their decision in Bilski in June of2010.33 The 
disputed claims in Prometheus involved methods of determining proper dosage levels of 
certain drugs used for "inflammatory bowel diseases".34 Upon remand, the Federal 
Circuit U.S. Court of Appeals set out solely to determine the issue of whether the method 
claims passed the initial screening test of § 101, that is, whether the patent claims sought 
to protect patentable subject matter.35 In rendering a decision, the court focused on the 
Supreme Court~s explanation in Bilski "that while a law of nature, natural phenomenon, 
31 See id at 3226-3227. 
32 Prometheus Labs., Inc. v. Mayo Collaborative Servs. & Mayo Clinic Rochester 628 
F.3d 1347 (Fed. Cir. 2010). 
33 See generally Mayo Collaborative Servs. v. Prometheus Labs., Inc.~ 130 S. Ct. 3543 
(U.S. 2010). 
34 See Prometheus Labs v. Mayo, 628 F.3d at 1350 (explaining that the administration of 
Thiopurine was found by Prometheus to treat certain gastrointestinal and autoimmune 
disorders). 
35 See id at 1353. 
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or abstract idea cannot be patented, 'an application of a law of nature or mathematical 
formula to a known structure or process may well be deserving of patent protection,'" 
though simply limiting an invention to a particular scientific field does not alone make an 
abstract scientific principle patentable. 36 Furthermore, the Court expressed that a given 
claim is "to be considered as a whole" when determining its patent-eligibility, not as 
individual parts.37 For this reason, purely "mental steps", though not patentable on their 
own by defmition, may be included as part of a longer method claim that contains 
redeeming patentable clauses. 38 However, in these cases, the redeeming, patentable steps 
must be "central to the purpose of the claimed process. "39 
Essential to the outcome in Prometheus was that the disputed claims used the 
steps of "administering" and "determining", two terms that will prove to be pivotal in the 
following: two. cases.described below. as .well. After. finding that the .claims represented. an, ...... . 
"application" of a law of nature and were thus patentable, the court went on to explain 
why, together, the "administering" and "determining" steps satisfied the "transformation" 
prong of the machine-or-transformation test.40 Though this case involved a method of 
treatment and not a genetic diagnostic test, the same rationale established in Prometheus 
has been used in both areas. Upon completing this two-part analysis and deciding that the 
method claims did not "wholly preempt all uses of the recited correlations", the Court 
ruled that the method claims were patentable subject matter under § 101.41 
36 See id. at 1354 (explaining a key principle established by the Bilski line of cases). 
37 See id at 1354 (explaining a rule set forth by the Supreme Court in Bilski v. Kappas). 
38 See id. at 1358 (agreeing with one of the holdings of the District Court below). 
39 See id. at 1355 (applying a rule set forth in In re Bilski). 
40 See id. 
41 See id. 
10 
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D. Myriad 
The next major diagnostic method patent holding after Bilski took place in the 
Federal Circuit U.S. Court of Appeals in Ass'n for Molecular Pathology v. USPTO 
("Myriad").42 Myriad involved three challenged method claims, each method somehow 
incorporating the newly patented BRCA gene sequences, which Myriad discovered were 
"associated with a predisposition to breast and ovarian cancers. "43 The first and second 
disputed method claims, which were analyzed together by the court, utilized the key 
terms "analyzing" and "comparing", respectively.44 The "analyzing" claim described a 
method of analyzing DNA to determine whether the BRCA 1 gene is altered in a certain 
way. 45 The "comparing" claim attempted to patent a method of essentially comparing a 
... healthy·BRCA 1. geneJo .a. tumoxous.BRCA.l gene.46 The court~Rt:wo-part test entaile.d.frrst·~_., ) ............ . ·._.., .. -~.~.,·. _. 
applying the machine-or-transformation test to the individual steps in the claim, then 
making a determination as to whether, as a whole, "the claim is not so 'manifestly 
abstract' as to claim only a scientific principle" and thus not be patentable. 47 By applying 
this two-part test, the court seemingly conformed to the Supreme Court's ruling in Bilski, 
not basing its determination solely on the machine-or-transformation test. The actual 
42 Ass'n for Molecular Pathology v. USPTO, No. 2010-1406, 2011 U.S. App. LEXIS 
15649 (Fed. Cir. July 29, 2011). 
43 See id at *10 (describing how Myriad patented the BRCAJ and BRCA2 genes 
themselves as well as several methods of looking for genetic mutations in those genes). 
44 See id. at *9-11. 
45 See id at *9-10. 
46 See id at *10-11. 
47 See id at *74 (borrowing the second test prong from the U.S. Court of Appeals 
decision in Research Corp. Techs. v. Microsoft Corp., 627 F.3d 859 (Fed. Cir. 2010) 
("Research Corp").). 
11 
significance of this second step~ however, still remained to be seen, as it admittedly had 
no effeqt in this instance. 
The court reasoned that because the "comparing" claim did "nothing more than 
[recite] the abstract mental steps necessary to compare two different nucleotide 
sequences", it fell short of being a "transformation".48 With regard to the "analyzing" 
claim, the court found that even though it was targeted toward analyzing a highly 
particular nucleotide sequence, pursuant to Bilski, this fact alone does not render an 
abstract idea patentable. 49 In summation~ the court proclaimed that both of these claims 
were absolutely unpatentable based on the above analyses as well as the fact that all the 
claims did, in reality, was "compar[e] two DNA sequences" and nothing more. 5° The 
court disagreed with Myriad's suggestion that "additional, transformative steps" should 
. ··" .. ·: •. _,..,,fHP"'-··~-a•,, .. be.'~read:.into;':the-Jllethod,claims,.pr:es.ented.? 1.,.Inso.holding,. the .. cnurt.set,a.ne.w . .standard .. _.., ........... .-,",.;·, .... "'-.. , ......... ~ 
for method claim review, namely that in order to satisfy the machine-or-transformation 
test, the court should hesitate to look beyond the words contained in the claims 
themselves for a "transformative step". 
The third Myriad method claim involved the three steps of"'growing' 
transformed cells", "'determining' the cells' growth rates", and "'comparing' the growth 
rates". 52 The court reasoned that as both the "growing" and "determining" steps required, 
to some extent, "physical manipulation of the cells", both of these steps satisfied the 
48 See id. at *68. 
49 See id at *69. 
50 See id. at *69 (holding that the first two method claims failed to satisfy the Machine-
or-Transformation Test for this reason). 
51 See id at *69. (reasoning that because "extracting" and "sequencing" were not actually 
anywhere in the claims themselves, these words could not simply be "read into" the 
claims to make them satisfy the transformation prong of the MoT Test). 
52 See id at *73-74. 
12 
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machine-or-transformation test. 53 Though the "comparing" step would not be patentable 
on its own, based on Prometheus, a single step's unpatentability is not defeating as to the 
claim taken in its entirety when the other, redeeming steps are the real key to the claimed 
method's purpose, which they indeed were. 54 As for part two of its analysis of the last 
method claim, the court indeed held that the claim was limited enough and "not so 
'manifestly abstract' as to claim only a scientific principle", thus satisfying the standard 
first announced in Bilski and later used in Prometheus. 55 For the foregoing reasons, the 
court held that of the three challenged Myriad method claims, only the claim containing 
three steps, two of them patentable on their own, was patent-eligible subject matter under 
§ 101.56 
The most recent diagnostic testing method claim patentability issue was decided 
in Classen I:mrhunotherapies, Inc. v. Biogen Idee ("Classen"), 57 which is widely 
anticipated to reach the Supreme Court on appeal sometime in the near future. Like 
Myriad, Classen involved three method claims. The first two claims covered were so 
similar, according to the court, that they chose only to use one for their analysis, "Claim 1 
53 See id at *73-74. 
54 See id. at *74. 
55 See id. at *7 4 (explaining that this ~as the case beca~se the "claim [did] not cover all 
cells, all compounds, or all methods of determining the therapeutic effect of a compound," 
but was rather "tied to specific host cells."). 
56 Even if only one of the three steps were patentable on its own, the claim likely still 
would have been deemed patentable since there was a transformation. See id at 7 5. 
57 Classen Immunotherapies, Inc. v. Biogen Idee, No. 2006-1634, 2006-1649, 2011 U.S. 
App. LEXIS 18126 (Fed. Cir. August 31, 2011). 
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of the 739 patent", and not examine the" '139 patent".58 These claims generally 
described a method of analyzing "immunization schedules" and administering 
immunization treatment based on the analysis, reciting the steps of "screening", which 
includes "identifying" and "comparing", and "immunizing". 59 According to Classen, all a 
potential infringer had to do to infringe upon these claims was "read[] the relevant 
literature and select[] and use[] an immunization schedule that is of lower risk for 
development of a chronic immune-mediated disorder". 60 The third disputed method 
claim, found in the" '283 patent", was directed toward the "screening'' portion of the first 
two claims.61 This claim covered the method of reviewing of"published information on 
the effects of immunization schedule" among different mammals "with respect to the 
occurrence of immune-mediated disorders," and did not include any type of active step, 
, such.asadministering.an.immunization,.as.the.first.two claims did.62 Classen argued,., ...... , ..... ~ .. ·-· ~··" ·--~, .. 
quite literally, that this patent could be infringed whenever any person reviews this type 
ofinformation.63 The court would recognize this, however, and find this lacking claim 
patent ineligible. 
The district court below found that all three Classen method claims failed to 
satisfy § 10 1 's requirements because they all "include[ d] the mental step of reviewing the 
58 See id at *6. 
59 See id at *6-7. 
60 See id at *7 (explaining Classen's argument that simply the use of the immunization 
would constitute a transformation in satisfaction of the MoT Test). 
61 See id at *8. 
62 See id at *8. 
63 Classen's argument alone showed that this claim was not limited to any particular use 
or application. See id. at *9. 
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relevant literature to determine the lower-risk immunization schedule."64 As it is no 
longer the case that a single mental step can invalidate an entire claim, the Court of 
Appeals altered their decision. For this reason, as well as because two of the three claims 
included a "specific, tangible application" step, § 101 was satisfied by those claims. 65 As 
expected, the (283 patent claim still did not satisfy § 101, a ruling in line with the court in 
Myriad that explained "without applying the data in a step of the overall method," a 
method that, as a whole, "simply collect[ s J and compare[ s J data" will rarely be declared 
patentable subject matter.66 So, in Classen, unlike in Myriad, the case essentially turned 
on the broader § 10 1 filter that uses overall abstractness as its criteria rather than on the 
machine-or-transformation test. 
The court proceeded to run the challenged method claims through the machine-or-
''"' ·· ;., . ,.. ..... ~ . transformation, test for,,go.o_d.-measure, :though.r this. analysis .would .expressly, have .no .. effect .......... , . ··~ -.~ , .... y,.,,. '-*l 
on the outcome. 67 As to the two patentable claims, the court decided that under the 
principles set forth in Prometheus, and for the same reasons, both included the requisite 
"transformative steps" in satisfaction of the machine-or-transformation test. 68 This was so 
because these two method claims included an immunization step, which was logically 
equivalent, in the court's opinion, to the "administering drugs" step in Prometheus, which 
64 This case was decided by the lower court before Bilski v. Kappas and Prometheus, 
which established that a single unpatentable step in a method claim was not necessarily 
defeating as to the whole claim. See id. at * 19. 
65 See id. at *24 (analyzing these two claims using the test set forth in Research Corp). 
66 See id. at *25. 
67 It was just common practice to do a two-step inquiry using the abstractness test and the 
MoT test in light of Prometheus and Myriad, though this was essentially the first of these 
three decisions to place more emphasis on the abstractness portion. See id. at *29. 
68 See id. at *29. 
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was also held patentable.69 As for the third, unpatentable claim, which solely involved 
making a determination based on reading literature, the court found no such 
"transformative step", so the machine-or-transformation test was failed. 70 The dissenting 
opinion, written by Judge Moore, took a wholly different approach, declaring that all the 
challenged method patents failed to attain § 101 subject matter patentability as they 
attempted to patent "basic and abstract" "fundamental scientific principle[ s]. " 71 
IV. The Debate Over Genetic Diagnostic Testing Method Patentability 
As the above cases have illustrated, this is an important question that will likely 
soon be decided once and for all upon Supreme Court review. Between 1980 and today, 
~ . .,~.·~~";. .. , .......... .the .u .. s ... P.atent.andl'rademarkOffice granted over 20,0QO..gene patents .claiming isolated 
DNA segments,72 quite an alarming number if one considers that there are only an 
estimated 20,000-25,000 genes in the human genome.73 As these types of patents, 
which claim only the genes themselves, are continually being granted and challenged 
unsuccessfully in numerous cases, disputing the validity of such claims has become 
rather futile practice. On the other hand, due to the uncertainty surrounding the § 101 
69 See id at *29 (explaining that the immunization, when administered, could be 
described as being metabolized by the patient's body and in effect transforming the 
make-up of their blood, similar to the reasoning behind the transformation in 
Prometheus). 
70 See id at *29-30. 
71 The majority specifically addressed and rejected each of the dissent's arguments. See 
id at 51. 
72 See Mueller, supra note 13, at 102. 
73 See The Science Behind the Human Genome Project: Basic Genetics, Genome Draft 
Sequence, and Post-Genome Science, HUMAN GENOME PROJECT SCIENCE, 
http://www.oml.gov/sci/techresources/Human_ Genome/project/info.shtml (last visited 
December 6, 2011). 
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patentability of genetic testing method claims and the constant teetering on the courts' 
behalf in regard to establishing a workable legal doctrine for such claims has left these 
types of claims open to dispute. Furthermore) due to the many public policy concerns 
associated with granting patents for genetic diagnostic testing methods, especially the 
limiting effect on availability of the best medical care for the public, many have felt a 
need to challenge these claims.74 However, there remains a question as to whether the 
biotechnological advances that have been made and that continue to be made would still 
be pursued if there were no expectation of patent protection over such findings. 
A. Arguments For the Patentability of Genetic Diagnostic 
. . , . ,. .. ·' ;-Because the.marketin .the. biotech .industr¥ is .currently so competitive, much. of, 
the focus understandably becomes gaining an advantage, mainly a financial one, so that 
further and more research can be conducted. And by what better means, in this industry, 
is there gaining an advantage than by discovering a gene linked to a disease and patenting 
it along with any diagnostic application of it, thus preventing anyone else from using or 
profiting off of it? For this reason, the majority of the arguments for allowing genetic 
diagnostic method patentability center around creating incentive to discover and 
innovate. As the patent statutes were intent on accomplishing, offering exclusivity of use, 
for a limited time, on one's invention theoretically promotes progress of the sciences 
using the old-fashioned, proven reward system, money. 
The U.S. is a breeding ground for biotechnology, and compared to the rest of the 
74 See Kane, supra note 25, at 26 ("Numerous amicus briefs filed in [Prometheus] noted 
the chilling effect of the method claims on the use of basic scientific facts."). 
17 
• 1. 4f ~ ~ .... • < ,, •• ,. ~ 
world, our industry is booming. No one would argue that it has done wonders for our 
economy and played a major role in getting this country to where it stands today. For this 
reason, it would be difficult to suggest such a drastic change such as taking away patent 
protection for diagnostic method patents, and possibly disrupt this thriving industry. 
Questions arise as to the effect this type of policy-making would have, such as whether it 
might discourage future growth in the industry or lead companies to venture elsewhere to 
conduct their research and obtain patents outside the U.S., as Judge Rader pointed out in 
his separate opinion to Classen. 75 In the biotechnology and pharmaceutical industry, 
"patents are seen as necessary to enhance an inventor's ability to recoup the substantial 
investments of many years and hundreds of millions of dollars necessary to bring a new 
drug or device to market."76 Some also believe that if there were no patent protection in 
this.area/'researclt would.not,be.done..to make. the .. discoveries on which .genetic tests are 
based, and the test would not be developed after the discovery was made." 77 This is 
clearly not the type of scenario the courts would want to create or the public would want 
to face. 
B. Arguments Against the Patentability of Genetic Diagnostic Methods 
75 Judge Rader's views were neither addressed nor taken into consideration by the 
majority, nor were they intended to be. In issuing this opinion, Judge Rader wished 
simply to bring these concerns to the attention of future courts hearing cases involving 
diagnostic method claim patentability, which he knew were not far off. See Classen v. 
Biogen, 2011 U.S. App. LEXIS 18126 at *45. 
76 See Mildred K. Cho et al., Effects of Patents and Licenses on the Provision ofClinical 
Genetic Testing Services, JOURNAL OF MOLECULAR DIAGNOSTICS, Feb. 2003, at 3 (noting 
also, though, that "it has been proposed that patents are not necessarily an effective 
incentive for the development of clinical genetic diagnostic tests."). 
77 See id at 3-4. 
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There are a number of reasons why so many argue against allowing patents over 
genetic diagnostic methods, mostly coming from a public policy standpoint. 
Substantiating the issue is the fact that once a laboratory discovers "a link between a 
disease and a precise genetic defect ... the respective diagnostic test can be relatively 
easily developed." 78 This essentially means that there is a potential for the number of 
genetic diagnostic testing method patents to increase exponentially as more and more 
genes are linked to disease, as multiple method patents may revolve around a single 
discovery.79 The biggest concern with allowing such patents, which indeed directly 
affects perhaps the largest number of people, is the consequential reduction of patient 
access to genetic diagnostic testing. 80 
... ~ ... As.noted..earlier,.genetic diagnostic testing provides doctors with the. ability to 
diagnose and warn patients of the existence or likelihood of genetic disorders for them 
and their offspring alike, valuable, occasionally life-saving information. However, no 
matter what the negative impact genetic diagnostic method patents may have, it all stems 
:from the ongoing monopolization of genetic testing. In line with the fear of restricting 
patient access to genetic testing is the concept of "monopoly rents, or excess profits 
attributable to the patent, [that] will be extracted :from those able to pay, to the detriment 
78 See Saini, supra note 5, at S13. 
79 See Kane, supra note 25, at 30 ("Potentially, any knowledge of the data point/primary 
fact- whether deliberately procured or assayed or incidentally obtained-will set up the 
possibility of infringement if the data is interpreted to arrive at a correlative 
conclusion/secondary fact."). 
80 See Mueller, supra note 13, at 102 (stressing the "critical importance to society of 
facilitating patient access to genetic testing" and patient access concerns studied by the 
Department of Health and Human Services Advisory Committee originating from the 
"restrictive licensing of some gene patents."). 
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of those patients effectively priced out of testing by the monopolist."81 Patent-holders of 
genetic testing methods are given the freedom "to dictate what kind of test may be done" 
or not be done and limit "the conditions for which testing may be done,"82 powers that do 
not belong in the hands of those profiting off of restricting access to care. For example, 
through Myriad is the only way a person may have a BRACAnalysis Test performed, and 
Myriad charges approximately $3,200 per test and does not accept all insurance plans. 83 
Not only does this monopolization restrict patient access to genetic testing, but it 
also restricts further research by the scientific community using known, patented 
methods, which clearly will have a wider-spread negative impact on society in the long 
run. 84 According to a research study conducted in 200 1, in which the researchers directly 
surveyed "clinical laboratory directors that perform DNA-based genetic tests", the effects 
of patents on these,technologies are.quite.reaL85 The survey determined that "[t]wenty-
five percent of respondents reported that they had stopped performing a clinical genetic 
test because of a patent or license," and "[fjifty-three percent of [all] respondents reported 
deciding not to develop a new clinical genetic test because of a patent or license."86 
Staggering numbers indeed if indicative of the entire population of genetic researchers, 
seeing as these were the results over ten years ago, one must assume that they have only 
increased since then in correlation to the increasing number of such method patents. 
Additionally finding that "[a]lmost two-thirds of the lab[] directors in [their] sample had 
been contacted [at some point] by a patent- or license-holder about the laboratory's 
81 See Merz, supra note 2, at 326. 
82 See id. at 327. 
83 See Mueller, supra note 13, at 111. 
84 See Merz, supra note 2, at 326-327. 
85 See Cho, supra note 76, at 3. 
86 See id 
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potential infringement [via] performance of a genetic test," the results of this study 
should shed some light on just how common and pervasive genetic testing method 
patents are.87 
V. Restricting Patentability by Abolishing the Machine-or-Transformation 
Test for Genetic Testing Claims and Permitting the Use of Patented 
Genetic Testing Methods for All Diagnostic and Research-Related Use 
In order to provide somewhat of an idea of the reality of patent abuse, which 
clearly is most detrimental when it directly affects people's health, a closer look into the 
background of Myriad may shed some light on just how far inventors will go to secure a 
. , .., ... , ... patent they. can use. to hlockall .. othet-use and benefit financially off of infringers. Mark . 
Skolnick, a researcher who was employed by the University of Utah, was taking part in 
the efforts of "an international consortium" to uncover the genetic marker for breast and 
ovarian cancer.88 The consortium had every intention of placing the gene into the public 
domain once they discovered it, most likely to fuel additional research using their 
discovery and in effect benefit society. 89 Instead, once the consortium got very close to 
pinpointing the disease gene and began sequencing the gene, Skolnck broke away and 
formed Myriad Genetics, taking the newly discovered BRCA genes with him and 
obtaining patents on the genes themselves as well as on the simple tests that could be 
87 See id at 5. 
88 See Joshua D. Sarnoff, Patent Eligible Medical and Biotechnology Inventions After 
Bilski, Prometheus, and Myriad, 19 TEX. INTELL. PROP. L.J. 393, 408 (2011). 
89 See id. at 408-409. 
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performed using the genes.90 Using his new gene and method patents to target any and all 
infringers in order to obtain royalties or sue for infringement, Myriad established a 
complete monopoly over the genes and prevented any research or diagnostic tests that 
utilized the BRCA genes from being performed.91 Clearly, this type of behavior must not 
be reinforced, and any incentive-creating, beneficial effect of granting patents in such 
instances is outshone by the potential for abuse and inhibition of the "progress of 
science" as a whole. In order to counteract these concerns, the courts must strike down 
more genetic testing methods as unpatentable for abstractness and overextending 
preemption and congress must put into place statutory exemptions to allow diagnostic 
uses and beneficial research to freely occur without risk of infringement. 
.-.-A.: AddressingJudicial-Guidelineslo Place Greater Limits on the Patentability of 
Genetic Diagnostic Testing Methods 
As long as the MoT Test remains in place, it will be incorrectly applied by courts 
and afforded far too much weight in all types of method claim cases, especially genetic 
testing method claims.92 As discussed above, the MoT Test was made relevant again by 
the In re Bilski court when they held, in what is widely understood as the judge's 
90 See id 
91 See id at 409 ("After the Myriad patents were granted, they were subjected to 
substantial public criticism in the United States (principally on utilitarian grounds) for 
interfering with research, for raising the costs of breast-cancer diagnostic treatment, and 
for preventing the use of a better (more comprehensive) diagnostic test that had been 
developed by others and was being used in Europe."). 
92 See Kane, supra note 25, at 32 ("The legal tests that originated with business method 
patent cases -the UCT and the MOT tests- are capable of dictating outcomes that may 
be directly opposite to the public domain protecting analysis of the preemption inquiry ... 
[t]hus, the tests may not be congruent; the relative weight accorded to the transformation 
analysis or the preemption analysis may be outcome-determinative."). 
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misinterpretation of an earlier Supreme Court holding, that this was to be the exclusive 
test for determining method patent eligibility.93 Judging from the subject matter in that 
case alone, it is difficult to justify how the court believed a test they felt should be applied 
to methods of hedging risk should also be applied to biotechnological method claims.94 
Because a transformative step is apparently accomplished quite easily according to the 
Court of Appeals with genetic testing method claims, this will result in many otherwise 
unpatentable abstract mental processes being declared patentable under the MoT Test.95 
Examples of this were seen in Prometheus and Myriad, where a strong argument 
existed that each of the method claims later deemed patentable by the court claimed 
"natural phenomena" and were overly broad in failing to claim the use of a "particular 
test method or device," factors that should defeat any claim under§ 101.96 However, both 
~ . courts .. seemed to. overlook this glaring, fatal insufficiency to focus more on the outcome 
of the MoT Test, which was easily satisfied in both cases and overwhelmingly outcome-
determinative. Placing their analysis under the guise of having evaluated the claim "as a 
whole", the Prometheus court mistakenly examined it "as a whole" to see if it could be 
deemed a transformation, not to determine whether the claim was sufficiently inventive 
93 See Minssen, supra note 24, at 5 ("In In re Bilski a majority of the Federal Circuit 
judges misinterpreted Supreme Court precedent holding the so-called 'machine or 
transformation' test (MOT) to be the sole applicable test for deciding upon patent-
eligibility for all process claims."). 
94 See id ("Although the facts of the case did not involve biotech or pharmaceutical 
subject matter but rather, a process for hedging risk in commodity markets, the decision 
implicitly included claims for biotechnological processes. The Court basically changed 
the patent eligibility examination from whether a claimed biotechnology process covered 
a 'fundamental principle' to whether or not it encompassed enough involvement of a 
machine or transformation."). 
95 See Kane, supra note 92, at 30-31. 
96 See id. at 30. 
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in its entirety as it should have, which would have likely led to a far different result. 97 In a 
similar holding, the Myriad court essentially held that as long as a genetic testing method 
claim exhibits at least one step that involves doing something, and not just steps that 
involve looking at something, and the patentee can show that the active step is important, 
the claim, as a whole, is patentable. 98 
The changes brought about by the Supreme Court in Bilski v. Kappas did little in 
reality to combat the clearly erroneous decision in In re Bilski, and further change is 
required. Immediately following the decision therein, the USPTO on June 28, 2010 
circulated a Memorandum among all patent examiners informing them of the Bilski v. 
Kappas decision and instructing them not only to continue applying the MoT Test to 
method patent applications, but informing them that basically all methods satisfying that 
test are patent -eligible .:'unless :there is a clear .indication that the method is directed. to an 
abstract idea."99 About a month later, the USPTO handed down an Interim Guidance, 
which unambiguously explained to patent examiners that method patents satisfying either 
prong ofthe MoT Test are almost never going to be patent-ineligible under §101 for 
abstractness. 100 Even in their interpretation of the court's decision, the USPTO 
conclusively afforded vastly greater important to the MoT Test over any other test or 
97 See Sarnoff, supra note 88, at 404 ("The Federal Circuit thus improperly allowed the 
newly discovered but ineligible correlation to contribute to the "invention" assessed for 
eligibility."). 
98 See id. at 414-415 (explaining that if the court would have treated the location of the 
BRCA genes correctly as biological facts, "it would be apparent that no creativity went 
into isolating the genetic DNA or identifying their sequences, particularly given the 
advanced state of genetic technologies at the time, or into using them for comparison 
once the sequences were known and the molecules were isolated."). 
99 This memo also instructed examiners to reject claims that failed to satisfy the MoT 
Test on that basis alone. See Minssen, supra note 24, at 62. 
100 The Interim Guidance also clearly said that it would very rarely, if ever, be the case 
that a method claim failing to satisfy the MoT Test would nonetheless be patentable. See 
id. at 63. 
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principle. So essentially, the current rule is that even though the MoT Test is no longer 
the exclusive test for determining genetic diagnostic testing method claim patentability, it 
is very nearly always the outcome-determinative test. For the above reasons, the 
Machine-or-Transformation has no place in the biotechnology context, and must be fully 
abandoned in cases involving genetic testing methods in favor of a new, much more 
difficultly satisfied legal examination, so that it can no longer be so disastrously 
misconstrued. 
B. Creating Statutory Exemptions for Diagnostic and Research-Related Uses of 
Genetic Diagnostic Testing Patents 
.. For those.g.enetic .diagnostic. method patents that do survive stricter judicial- ·. 
analysis and USPTO review, such patent holders must still not be able to detrimentally 
cease all research and diagnostic activity using their patented methods. In order to 
legislatively reinforce the policy of inhibiting the overly restrictive, crippling use of 
genetic testing method patents by their patent holders in such important fields as genetic 
diagnostics and research, Congress must create an overarching statutory exemption for 
such uses. Rather than completely banning the patenting of medically related diagnostic 
methods altogether, as most countries indeed do without suffering heavy 
consequences, 101 and risking disturbing the current U.S. patent system to a fault as 
discussed earlier, such statutory exemptions would serve only to limit the liability of two 
101 See Sarnoff, supra note 88, at 407 ("Unlike in the United States ... most countries 
entirely prohibit patents on medical methods of diagnosis and treatment."); See Mueller, 
supra note 13, at 112 ("Germany, Japan, and the U.K. have long included a research use 
exemption in their domestic patent laws. These patent systems have not fallen apart 
because of the exemption, nor has innovation in these countries stopped."). 
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types of literal infringers, leaving patents enforceable in all other instances. 102 For the 
same reasons, the use exemptions put in place must not be applied retroactively, and all 
pre-existing patents should be entitled to the same protections they were afforded at the 
time they were granted, leaving them vulnerable only to stricter judicial review. 103 
Similar to the Fair Use Doctrine of Copyright Law, which affords non-liability for 
copyright infringement in only certain non-commercial or non-exploitative 
circumstances, the broad liability exemption for certain uses of genetic testing method 
patents should be targeted solely toward benefiting the furtherance of research, public 
health, and greater access to healthcare, not the commercial use and profiting off of those 
patented inventions. 104 As suggested by the Secretary's Advisory Committee on Genetics, 
Health, and Society, the diagnostic use of genetic testing method patents for at least 
""patient.care': reasons-should not only constitute non-infringement, but also "no 
remuneration [should be] due to the patentee" and the exemption should apply to all 
laboratories wishing to use those diagnostic methods, not just non-commercial ones. 105 
102 See Mueller, supra note 13, at 115 ("Specifically, the proposed exemptions would 
allow unlicensed use of gene patents for research and diagnostic, but not therapeutic, 
~urposes. "). 
03 See id at 113 ("So as not to unduly disrupt those reliance interests, legislators should 
consider implementing any liability exemption (or compulsory licensing scheme) in a 
prospective-only manner" even though "a prospective implementation would not 
necessarily address the immediate problem of access to the patented BRCAJ/2 genes."). 
104 See id at 112 ("Many scholars have advocated a statutory exemption in U.S. patent 
law from infringement liability when researchers use patented materials for non-
commercial purposes such as research and experimentation-a sort of 'fair use' doctrine 
for patent law."). 
105 The SACGHS report proposed a "liability exemption, which would apply when 
patented genetic tests are offered for 'patient-care' (i.e., diagnostic) purposes" and 
supported the position that "no act of infringement and no remuneration [should be] due 
to the patentee, analogous to the operation of fair use in copyright law." It further held 
that the exemption "would apply to both non-commercial and commercial laboratories." 
See id at 115. 
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At the very least, a diagnostic use exemption should allow patent-holders to 
charge users only reasonable royalties for their patented invention and not the inflated 
royalties they are likely to charge due to their test monopolization, which is the preferred 
method by many advocates and chosen as the best method by a recent survey. 106 Along 
those same lines would be the enforcement of required compulsory licensing for 
"physicians providing medical services" in exchange for reasonable royalties, thus 
"preserving the patent system's incentives" function. 107 Compulsory licensing describes a 
system in. which "an official instance or a court forces the patent holder to grant a license 
to a third party."108 On its face, this would seem to greatly alleviate the high costs and 
lower availability associated with genetic testing monopolization while still giving patent 
holders the ability to financially profit off such uses. However, any remuneration at all 
seems unnecessary, as -patentees would .still be able to freely obtain licensing.fees or sue ~·. 
for infringement anyone who uses their patented methods for other uses. 109 This is why 
full genetic diagnostic and research use exemptions remain the preferred method, though 
not the only viable method, of striking a balance between public health concerns and 
maintaining incentives to invent, tipping perhaps only slightly in favor of the public as it 
should. 
106 See Saini, supra note 5, at S30 ("Clinical use exemption was held as the best remedy 
regarding patents in a Swiss survey."). 
107 See Merz, supra note 2, at 329. 
108 See Saini, supra note 5, at S27 (defining "compulsory licenses"). 
109 See Mueller, supra note 13, at 115-116 ("The [SACGHS] committee does not 
consider remuneration for patient-care purposes to be necessary, because the continued 
enforceability of gene patents against therapeutic uses would be sufficient to preserve 
incentives for the development of gene based therapeutics."). 
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VI. Conclusion 
The U.S. Patent system that was put in place around the same time this country 
was founded has more than proven that it works. The U.S. has been the source of 
countless inventions, many of which dominate the world market in a given field. 
However, our patent system is no longer identical to what it was when it was first set into 
motion, as the need for change was continually recognized and the patent system adjusted 
accordingly to further enhance the progress of science. In this highly technological age in 
which new findings are being made nearly every day in highly complex fields that are 
perhaps worthy of patent protection, inventors from all over the world have relied upon 
the very inventor-friendly patent system that is in place in the U.S. Though it can easily 
. he argued-that.our-patent.system.has.:.~.worked'~ thus-far and should continue on 
unchanged for that reason, sometimes alterations must be made to make such a practice 
more efficient, more up to date, and more universally beneficial. The widespread abuse 
and exceedingly detrimental use of patents in the ever-expanding biotechnology industry 
today should alert us of this need for reformation in the form of judicial and legislative 
involvement. The continued practice of permitting the use of overly broad genetic testing 
method patents to prevent research and diagnostic testing performed for the benefit of 
either ill or at-risk members of society is not only affecting the present community at 
large, but also placing unnecessary roadblocks in the path to future discoveries. The best 
way to cease and deter this type of activity is through the enactment of diagnostic and 
research use exemptions and the abandonment of outdated, inapplicable legal 
patentability tests in favor of more restrictive ones. 
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